Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.
Recordati disclosed that UBS Europe SE, acting as an intermediary, executed a series of purchases of Recordati shares on the Italian regulated market in January 2026 as part of the company’s ongoing share buy-back program launched in December 2025. Over multiple trading days between 2 and 21 January 2026, UBS Europe acquired tranches of Recordati treasury shares on the EXM market in Milan at average weighted prices around €47–49 per share, supporting the reduction of free float and potentially enhancing capital structure flexibility and shareholder value over time.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica SpA (Recordati) is an Italian pharmaceutical company based in Milan, operating in the healthcare sector with a focus on prescription medicines and related pharmaceutical products, and its shares are listed on the Italian stock market.
Average Trading Volume: 309,952
Technical Sentiment Signal: Hold
Current Market Cap: €9.95B
See more data about REC stock on TipRanks’ Stock Analysis page.